Table 1.
Baseline characteristics and treatment exposure in all participants enrolled and receiving at least one dose of treatment (N = 75) in the study
| Placebo | Crenezumab | ||||
| (n = 14) | 30 mg/kg | 45 mg/kg | 60 mg/kg | 120 ⟶ 60 mg/kg | |
| (n = 10) | (n = 11) | (n = 21) | (n = 19) | ||
| Mean age, years (range) | 71.4 (57–84) | 73.4 (54–82) | 73.3 (57–82) | 72.9 (51–87) | 69.4 (54–88) |
| Male, n (%) | 6 (42.9) | 6 (60.0) | 4 (36.4) | 13 (61.9) | 10 (52.6) |
| ApoE status, n (%) | |||||
| E2/E3 | 1 (7.1) | 0 | 0 | 0 | 1 (5.3) |
| E2/E4 | 0 | 0 | 0 | 0 | 1 (5.3) |
| E3/E3 | 3 (21.4) | 4 (40.0) | 1 (9.1) | 4 (19.0) | 5 (26.3) |
| E3/E4 | 8 (57.1) | 6 (60.0) | 7 (63.6) | 14 (66.7) | 7 (36.8) |
| E4/E4 | 2 (14.3) | 0 | 3 (27.3) | 3 (14.3) | 5 (26.3) |
| MMSE score, mean (SD), range | 20.9 (2.8), 18–25 | 23.3 (3.8), 18–28 | 22.2 (2.7), 18–26 | 23.2 (3.3), 18–29 | 22.9 (3.1), 18–28 |
| Median duration of crenezumab exposure, | 132.43 (12.1–196.6) | ||||
| weeks (range)a | |||||
aMedian duration of exposure is reported for participants who enrolled in the open-label extension period (crenezumab 30/45 mg/kg, n = 23; crenezumab 60 mg/kg, n = 48). ApoE, apolipoprotein E; MMSE, Mini-Mental State Examination.